Full-Time
Senior Director
Portfolio Strategy and Analytics
Neurocrine Biosciences
1,001-5,000 employees
Develops and markets neurology-focused therapies
Compensation Overview
$226.5k - $309k/yr
Company Does Not Provide H1B Sponsorship
San Diego, CA, USA
In Person
Bachelor's, Master's, MBA, PharmD, PhD
 Biology & Biotech (1) |
|---|
Get referred to Neurocrine Biosciences
See people who can refer or advise you
- BS/BA degree in Life Sciences, Business, Finance, Engineering, Data Analytics, Operations Research, or related discipline and 14+ years of relevant pharmaceutical, biotechnology, healthcare, consulting, portfolio management, strategy, or related industry experience
- Master's degree in a related discipline and 12+ years of relevant experience
- PhD, PharmD, MBA, or other advanced degree and 10+ years of relevant experience
- Deep understanding of pharmaceutical drug development across discovery, preclinical, clinical, regulatory, and commercialization stages
- Significant experience managing multi-year compound flow models and portfolio forecasting methodologies
- Expert knowledge of portfolio strategy, portfolio management, resource planning, and investment decision-making frameworks
- Extensive experience supporting portfolio governance processes and executive-level decision-making
- Advanced experience with Planisware or comparable portfolio management and planning platforms
- Experience implementing, managing, or optimizing portfolio planning systems, analytics capabilities, and governance processes
- Strong understanding of portfolio valuation, probability of success modeling, scenario planning, forecasting techniques, and portfolio optimization methodologies
- Experience leading enterprise portfolio planning and prioritization processes across complex, multi-asset development portfolios
- Demonstrated success influencing senior leaders and facilitating executive-level portfolio prioritization, investment, and resource allocation decisions
- Experience developing multi-year portfolio strategies and long-range planning scenarios aligned with organizational objectives
- Experience supporting executive governance committees, portfolio review forums, and strategic planning processes
- Strong understanding of R&D financial planning, budgeting, forecasting, and resource allocation processes
- Experience leading portfolio benchmarking and competitive operational analyses
- Experience preparing executive leadership and Board-level presentations and materials
- Familiarity with AI-enabled analytics tools, advanced modeling techniques, and external benchmarking resources preferred
- Ability to evaluate portfolio risks and opportunities and translate findings into strategic recommendations that influence organizational strategy and investment decisions
- Strong strategic thinking, business acumen, and ability to integrate scientific, operational, financial, and portfolio considerations into decision-making
- Exceptional communication, influence, stakeholder management, and relationship-building skills
- Demonstrated ability to communicate complex analyses and strategic recommendations to diverse audiences, including senior executives
- Strong analytical, critical thinking, problem-solving, and decision-making capabilities
- Proven ability to lead through influence and achieve results within highly matrixed organizations
- Demonstrated ability to develop innovative solutions to complex business challenges with significant organizational impact
- Strong planning, prioritization, organizational, and project leadership skill
- Ability to manage multiple competing priorities in a dynamic and evolving portfolio environment
- Demonstrated ability to build partnerships and align stakeholders across functions and organizational levels
- Strong attention to detail while maintaining an enterprise-wide perspective
- Ability to mentor, coach, and develop others while fostering a culture of accountability and continuous improvement.
- Advanced proficiency with portfolio management, business planning, analytics, forecasting, and reporting tools
- Leads development and execution of enterprise portfolio strategy, prioritization, and optimization frameworks aligned with corporate and R&D objectives
- Owns and manages Neurocrine's multi-year compound flow model, including risk-adjusted and non-risk-adjusted portfolio scenarios across therapeutic areas and development stages
- Develops and maintains transition probability models across development stages and modalities to support portfolio forecasting, investment planning, and strategic decision-making
- Leads executive-level portfolio prioritization and trade-off discussions, translating complex portfolio data into actionable recommendations that support portfolio investment and resource allocation decisions
- Evaluates portfolio opportunities, risks, development scenarios, and investment alternatives to maximize overall portfolio value
- Designs and oversees quantitative models supporting portfolio forecasting, probability of success analyses, development timelines, resource planning, and investment decision-making
- Develops scenario analyses evaluating the impact of adding, removing, accelerating, delaying, or restructuring portfolio programs
- Analyses pipeline progression, development productivity, attrition rates, cycle times, and key portfolio performance indicators to support strategic planning and governance discussions
- Leads enterprise resource planning and capacity forecasting activities across functions, therapeutic areas, and development stages
- Partners with Finance, Program Management, and functional leaders to align portfolio objectives with organizational capacity, budgetary constraints, and long-range planning assumptions
- Develops portfolio-level financial models supporting annual operating plans, investment prioritization, resource planning, and budget forecasting activities
- Identifies resource constraints, operational risks, and strategic opportunities and develops recommendations to optimize portfolio execution
- Serves as business owner and subject matter expert for portfolio planning systems, including Planisware and related portfolio management platforms
- Establishes portfolio data standards, governance processes, and analytics best practices to support high-quality portfolio decision-making
- Drives implementation and continuous improvement of portfolio analytics tools, systems, reporting capabilities, and governance processes
- Leads benchmarking initiatives evaluating development timelines, costs, resource models, productivity metrics, and industry best practices
- Leverages AI-enabled tools, external data sources, and advanced analytics methodologies to enhance portfolio insights, forecasting accuracy, and competitive benchmarking capabilities
- Develops executive dashboards, portfolio reviews, governance materials, and Board-level presentations
- Provides analytical support for business development evaluations, external innovation opportunities, and strategic investment assessments
- Leads cross-functional portfolio planning processes and governance forums to drive alignment, transparency, accountability, and execution excellence
- Serves as a trusted advisor to executive leadership on portfolio strategy, prioritization, resource allocation, and long-term planning decisions
- Provides leadership, coaching, and mentoring to team members and cross-functional partners
- Other duties as assigned
- Familiarity with AI-enabled analytics tools, advanced modeling techniques, and external benchmarking resources preferred
Neurocrine Biosciences develops and commercializes medicines for neurological and endocrine diseases. Its work centers on discovering and developing treatments, with INGREZZA (valbenazine) approved to treat adults with tardive dyskinesia and a pipeline of other drug candidates in various clinical stages. The company earns revenue from sales of approved medicines and from milestones and royalties from collaborations with partners. By focusing on both neurological and endocrine conditions, Neurocrine targets patients and healthcare professionals seeking therapies for conditions such as tardive dyskinesia, Parkinson's disease, and endometriosis. Its main goal is to bring therapies to market through development and commercialization, supported by ongoing research across its clinical programs to address unmet medical needs in these areas.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1992
Get referred to Neurocrine Biosciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue jumped 39% to $959 million, beating estimates by 6%.
- Management raised 2026 INGREZZA guidance to $2.825-$2.875 billion on July 30, 2026.
- Soleno closed May 18, 2026, adding VYKAT XR and a $1 billion credit line.
What critics are saying
- The DOJ CID from August 2025 targets INGREZZA marketing and threatens criminal referrals.
- Zydus's generic INGREZZA SPRINKLE case in Delaware threatens INGREZZA exclusivity by 2027.
- INGREZZA concentration leaves Neurocrine exposed; a loss there guts growth and valuation.
What makes Neurocrine Biosciences unique
- INGREZZA commanded $716 million in Q2 2026, sustaining leadership in tardive dyskinesia.
- CRENESSITY posted $184 million Q2 2026 sales, widening Neurocrine's endocrine franchise.
- Neurocrine launched NBIP-1968 on August 7, 2026, building an internal obesity platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Parental Leave
Health Insurance
Dental Insurance
Vision Insurance
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Neurocrine Biosciences announces initiation of Phase 1 clinical study evaluating NBIP-'1968, a glp-1/gip/glucagon receptor triple agonist. Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. "Obesity is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "NBIP-'1968 is designed to engage three complementary metabolic mechanisms, reflecting our commitment to exploring multiple scientific approaches to obesity." The Phase 1 study initially will evaluate the safety and tolerability of single ascending doses of NBIP-'1968 in adult participants across a range of body mass index categories, including overweight and obese. Innovations in treatment by Neurocrine bioscience. NBIP-'1968 is an internally discovered, investigational long-acting triple agonist designed for once-weekly subcutaneous administration. It targets the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon to influence metabolic pathways involved in appetite regulation, energy balance and glycemic control. NBIP-'1968 was designed with balanced glucagon receptor activity to optimize the potential metabolic benefits of glucagon receptor activation while supporting tolerability. Neurocrine is developing NBIP-'1968 as part of a broader obesity portfolio that includes NBIP-'2118, an investigational corticotropin-releasing factor type 2 receptor agonist currently in Phase 1 development. NBIP-'1968 is intended for use in a fixed-dose combination with NBIP-'2118. The company's obesity research also includes earlier-stage programs designed to explore complementary mechanisms and extended dosing intervals. "Advancing NBIP-'1968 into the clinic marks another important step in building our obesity portfolio," said Jude Onyia, Ph.D., Chief Scientific Officer, Neurocrine Biosciences. "Our strategy is to explore complementary and differentiated mechanisms that may improve weight loss, preserve lean mass and ultimately address the diverse needs of people living with obesity." About Obesity Obesity is a chronic disease characterized by excess body fat and is associated with serious health conditions, including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis/fatty liver disease, certain cancers and osteoarthritis. It is driven by complex biological, environmental, and genetic factors - not simply lifestyle or willpower. Obesity has reached epidemic levels worldwide, affecting a significant proportion of adults and placing a substantial burden on public health systems. Despite recent advances in treatment, there remains a need for additional therapies that support safe, effective and sustainable long-term weight management. Current therapies can have challenges with respect to gastrointestinal tolerability, dose titration, and muscle loss. More news. August 7, 2026 August 6, 2026
Neurocrine Biosciences reported revenue of $959 million for the quarter ended June 2026, marking a 39.5% year-on-year increase. The figure surpassed the consensus estimate of $901.54 million by 6.37%. Earnings per share came in at $2.85, up from $1.06 a year earlier and beating the consensus estimate of $2.26 by 26.11%. Product sales reached $954.3 million, exceeding analyst estimates of $881.08 million. INGREZZA sales totalled $716 million, above the $628.59 million forecast, whilst CRENESSITY generated $184 million against an estimated $170.78 million. Collaboration revenue came in at $4.7 million, below the $6.02 million estimate and down 14.6% year-on-year. Shares rose 7.8% over the past month.
Neurocrine Biosciences releases Q2 2026 financial results. Neurocrine Biosciences, Inc. AlphaStreet Newsdesk powered by AlphaStreet Intelligence NBIX | EPS $2.85 vs $1.94 est (+46.9%) | Rev $959.0M vs $888.2M est (+8.0%) | Net Income $144.4M Neurocrine Biosciences, Inc. delivered a blowout second quarter, crushing Wall Street expectations as the neuroscience-focused company posted non-GAAP earnings per share of $2.85, well above the $1.94 analyst consensus and representing a beat of 46.9% based on estimates from 14 analysts. Revenue of $959.0M exceeded the $888.2M forecast by 8.0%, marking a sharp acceleration in growth for the San Diego-based biopharmaceutical firm. Earnings call transcripts The company's performance reflected surging demand across its portfolio, with revenue climbing 39.0% from $688.0M in the year-ago quarter. Adjusted net income reached $296.7M as Neurocrine continued to expand its footprint in the treatment of neurological and endocrine disorders. The strong quarterly results were powered by INGREZZA, the company's flagship tardive dyskinesia treatment, which generated $716.0M in revenue and grew 15.0% year-over-year, cementing its position as a leading therapy in movement disorders. Looking ahead, Neurocrine set full-year revenue guidance at $2.83B to $2.88B, reflecting confidence in sustained momentum across its commercial portfolio. The company has been capitalizing on expanding indications and market penetration for its approved therapies while advancing its pipeline of novel treatments targeting central nervous system conditions. A detailed analysis of Neurocrine Biosciences, Inc.'s quarter follows shortly on AlphaStreet. This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content. Discover more Company profile database Brokerages & Day Trading Stock research tools
Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, up 39% year-over-year. The San Diego-based biopharmaceutical company raised its full-year guidance for INGREZZA to $2.825–$2.875 billion, up from $2.7–$2.8 billion. INGREZZA net product sales reached $716 million in the quarter, reflecting 15% growth. CRENESSITY sales totalled $184 million, whilst VYKAT XR contributed $54 million following the May acquisition of Soleno Therapeutics. The company completed its $2.9 billion acquisition of Soleno in May 2026, paying $53 per share in cash. Neurocrine also secured a $1 billion revolving credit facility for general corporate purposes. GAAP net income was $144 million, compared with $108 million in the prior-year period. Non-GAAP net income reached $297 million versus $166 million a year earlier.
Neurocrine Biosciences (NASDAQ:NBIX) director sells $227,512.50 in stock. July 30, 2026 Key points. * Director Leslie Norwalk sold 1,250 Neurocrine Biosciences shares for approximately $227,513 under a pre-arranged Rule 10b5-1 plan, reducing her direct holdings by 44.05% to 1,588 shares. * Neurocrine reported quarterly earnings of $2.85 per share, beating estimates of $1.66, while revenue rose 39.5% year over year to $959 million. The stock traded near its 12-month high at $185.50. * Analysts maintain a "Moderate Buy" consensus with an average price target of $194.05; institutional investors own 92.59% of the company's shares. * MarketBeat previews top five stocks to own in August. Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Leslie Norwalk sold 1,250 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total transaction of $227,512.50. Following the transaction, the director directly owned 1,588 shares in the company, valued at approximately $289,031.88. This represents a 44.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Neurocrine Biosciences price performance. Neurocrine Biosciences stock traded up $4.71 during mid-day trading on Thursday, hitting $185.50. The company's stock had a trading volume of 2,170,803 shares, compared to its average volume of 1,182,411. The business has a 50 day moving average price of $167.01 and a 200-day moving average price of $145.90. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The stock has a market cap of $18.65 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 0.77 and a beta of 0.39. Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $2.85 EPS for the quarter, topping the consensus estimate of $1.66 by $1.19. Neurocrine Biosciences had a return on equity of 19.79% and a net margin of 21.55%.The firm had revenue of $959.00 million for the quarter, compared to the consensus estimate of $891.16 million. During the same quarter in the previous year, the business earned $1.65 earnings per share. The company's quarterly revenue was up 39.5% on a year-over-year basis. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 7.11 earnings per share for the current fiscal year. Analyst upgrades and downgrades. A number of equities research analysts have issued reports on the stock. Weiss Ratings raised shares of Neurocrine Biosciences from a "buy (b-)" rating to a "buy (b)" rating in a report on Tuesday. Needham & Company LLC restated a "buy" rating and set a $185.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 6th. Zacks Research upgraded shares of Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, June 23rd. Leerink Partners raised their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 22nd. Finally, Guggenheim lifted their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $194.05. Discover more Financial News Derivatives Institutional trading of Neurocrine Biosciences. A number of hedge funds have recently made changes to their positions in NBIX. DJE Kapital AG purchased a new position in Neurocrine Biosciences during the fourth quarter valued at $28,000. Geneos Wealth Management Inc. grew its stake in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock worth $25,000 after acquiring an additional 135 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Neurocrine Biosciences by 651.6% during the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company's stock valued at $33,000 after acquiring an additional 202 shares in the last quarter. Basecamp Wealth Advisors LLC raised its position in shares of Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company's stock worth $31,000 after purchasing an additional 204 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new position in Neurocrine Biosciences in the 1st quarter worth about $33,000. 92.59% of the stock is owned by institutional investors. About Neurocrine Biosciences. Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research-driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities. The company's lead marketed product, Ingrezza(TM)(valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Neurocrine Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list. While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.